Phase 2 N=49 Safinamide for Multiple System Atrophy (MSA)
Multiple System Atrophy
Primary: TEAEs (Treatment Emergent Adverse Events) and SAEs (Serious Adverse Events) — 52; 28; 49; 21 events
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=9 Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins
Multiple System Atrophy
Primary: Number of Adverse Events up to Six Months Post-treatment — 43; 0 Adverse events
Phase 2 N=58 AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients
Multiple System Atrophy, MSA
Primary: Striatum Brain Region: Change From Baseline in Microglia Activation Via Positron Emission Tomography(PET) — -0.23; 0.12; -0.35 ml/cc — p=0.13
Phase 2 N=174 Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)
Multiple System Atrophy
Primary: Change From Baseline to Week 48/Termination Visit in the Total Unified Multiple System Atrophy Rating Scale (UMSARS Part I and II) — 7.2; 7.8 units on a scale — p=0.6984
Phase 2 N=50 Exenatide Once-weekly as a Treatment for Multiple System Atrophy
Multiple System Atrophy
Primary: Change in UMSARS Score (Parts I+II) From Baseline — 6.1; 13.3 score on a scale
Phase 2 N=158 A Study of TAK-341 in Treatment of Multiple System Atrophy
Multiple System Atrophy
Primary: Change From Baseline in Modified Unified Multiple System Atrophy Rating Scale (UMSARS) Part I Total Score at Week 52 — 5.58; 5.54 score on a scale — p==0.961
Phase 3 N=92 Progression Rate of MSA Under EGCG Supplementation as Anti-Aggregation-Approach
Multiple System Atrophy
Primary: Change of Score in Motor Examination (ME) of the Unified MSA Rating Scale (UMSARS-ME) From V1 to V7. — 5.66; 6.60 score on a scale — p=0.51
Phase 3 N=336 Study of BHV-3241 in Participants With Multiple System Atrophy
Multiple System Atrophy
Primary: Change From Baseline in the Modified UMSARS Score at Week 48 — 5.20; 4.85 units on a scale — p=0.4656
N/A N=20 Transcranial Magnetic Stimulation in Spino-Cerebellar Ataxia
Spinocerebellar Ataxia
Primary: Percent Change From Baseline to Post Treatment on the Scale for the Assessment and Rating of Ataxia (SARA) — -25.9; -27.8 percentage change — p=0.29
Phase 2 N=15 Treatment of Parkinson Disease and Multiple System Atrophy Using Intranasal Insulin.
Parkinson Disease · Multiple System Atrophy
Primary: Change in Verbal Fluency FAS (F, A or S Words) Total Score — 38.8; 41.0; 32.8; 30.8 Words
Phase 2 N=90 Image Parkinson's Disease Progression Study
Parkinson's Disease
Primary: Change in Free-water Accumulation in the Substantia Nigra — 0.0009; 0.0041 arbitrary units (A.U.s)
N/A N=221 Evaluation of Clinical Decision Support System-mPDia for Neurodegenerative Parkinsonism Using MRI Images
Diagnoses Disease
Primary: Sensitivity of mPDia for the Diagnosis of Neurodegenerative Parkinsonism — 94.30 percentage
N/A N=21 Could Tai-chi Help Maintain Balance of Spinocerebellar Ataxia Patients
Spinocerebellar Ataxias · Tai Chi
Primary: Scale for the Assessment and Rating of Ataxia(SARA) — 11.5; 9 score on a scale
Phase 4 N=40 Namenda (Memantine) for Non-motor Symptoms in Parkinson's Disease
Parkinson's Disease
Primary: Unified Parkinson Disease Rating Scale (UPDRS). — 12; 12; 10; 10 units on a scale
Phase 2 N=110 Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study
Multiple Sclerosis
Primary: Expanded Disability Status Scale (EDSS) Improvement — 3.4; 3.3; 2.5; 3.7 units on a scale
N/A N=30 Investigating Central Neurophysiologic Correlates of Non-Motor Symptoms of Parkinson's Disease
Parkinson Disease · Autonomic Dysfunction · Depression
Primary: Change in Frontal Midline Theta EEG Power After Brain Stimulation — 1.03; 0.44; 1.01 microvolts^2/Hz — p=0.08
N/A N=61 Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP)
Progressive Supranuclear Palsy
Primary: Efficacy of Coenzyme Q10 (Unified Parkinson's Disease Rating Scale [UPDRS] AND Progressive Supranuclear Palsy Rating Scale [PSPRS]) — 5.9; 11.8; 11.5; 12.8 units on a…
Phase 2 N=37 ATX-MS-1467 in Multiple Sclerosis
Multiple Sclerosis
Primary: Change From Baseline in the Average Number of Time Constant 1 (T1) Contrast-enhanced Lesions (CELs) Over On-treatment Scans — 7.4; -2.4 lesions
Phase 3 N=536 A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS
Multiple Sclerosis · Spasticity, Muscle
Primary: Change From Baseline in Total Numeric-transformed Modified Ashworth Scale Score of the Most Affected Limb (TNmAS-MAL) — -1.7; -2.0; -1.4 units on a scale
N/A N=183 Computer Assisted Cognitive Rehabilitation for Persons With Multiple Sclerosis
Multiple Sclerosis
Primary: Neuro-cognitive Competence in Daily Living - California Verbal Learning Test-II — 56.1; 53.6 units on a scale — p=0.926
Early Phase 1 N=46 Assessment of Renal Function by Multiparametric MRI
Renal Impairment
Primary: T1 Time — 1500 ms
Phase 3 N=195 Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
Symptomatic Neurogenic Orthostatic Hypotension
Primary: Change From Baseline in Orthostatic Hypotension Symptom Assessment (OHSA) Question #1 Score at Week 4 — -1.69; -1.45 score on a scale — p=0.574
N/A N=1,147 Carotid Structure and Function in MPS Syndromes: A Multicenter Study of the Lysosomal Disease Network
Mucopolysaccharidoses
Primary: Carotid Intima-media Thickness, Measured in Millimeters — 0.44; 0.52; 0.56 mm
Phase 2 N=11 Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy
Progressive Supranuclear Palsy
Primary: Adverse Events — 23 Number of Adverse Events
N/A N=56 In-Home Care for Patients With PSP and Related Disorders
Progressive Supranuclear Palsy · Dementia With Lewy Bodies · Multiple System Atrophy
Primary: Change in Patient Quality of Life as Measured by the EuroQol 5-D (EQ-5D) Scale Between Baseline (Visit 1) and 1 Year (Visit 4) — 1; 0.5; 0.5; 0 units on a scale — p=0.59
Phase 2 N=32 Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis
Multiple Sclerosis
Primary: Percentages of Patients With Treatment-emergent Adverse Events (TEAEs) or Treatment-emergent Serious Adverse Events (TESAEs) — 100; 100; 88.9; 100 percentage of…
Phase 2 N=82 Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease (Stages I-IV, REM Sleep Behavior Disorder) and Controls
Parkinson Disease · REM Sleep Behavior Disorder · Healthy
Primary: Change in Sensitivity of QSM MR Imaging From Baseline MR Imaging to 24 Month MR Imaging — 379.5896; 314.1832; 561.1894; 288.1832 ppb — p=0.66
Phase 2 N=94 GM1 Ganglioside Effects on Parkinson's Disease
Parkinson Disease
Primary: Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) Motor Score From Baseline to Week 24 Assessed Off Medication. — -3.57; 1.85 Scores on a scale…
N/A N=54 Alpha MSH in Ocular Disease
Advanced Dry Macular Degeneration
Primary: Level of Alpha Melanocyte Stimulating Hormone as Measured by Enzyme-linked Immunosorbent Assay
N/A N=3 Spinal Cord Stimulation in Spinal Muscular Atrophy
Spinal Muscular Atrophy Type 3 · Spinal Muscular Atrophy Type 4
Primary: Muscle Weakness — 2; 3 Participants